Business
Hardman Research: SCIB development update
Hardman Research: SCIB development update.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 2051Z Scancell Holdings Plc 13 March 2017 \n\nHardman Research: SCIB development update\nSCIB development update: Scancell is a clinical stage pharmaceutical company developing two distinct flexible cancer immunotherapy platforms, each with broad applications. ImmunoBody is a DNA vaccine which stimulates high avidity anti-tumour T-cells for use as a monotherapy or in combination with checkpoint inhibitors. Moditope targets modified antigens and stimulates powerful anti-tumour T-cell responses for use in advanced and hard-to-treat cancers. Both platforms are targeting multi-billion dollar markets. 2017 will concentrate on raising the necessary funds to enable the commencement of a Phase II SCIB1 trial in combination with a checkpoint inhibitor. \nPlease click here for the full report:\nhttp://hardmanandco.com/docs/default-source/company-docs/scancell-documents/sclp---interim-scib-update---13th-march-2017.pdf\n\n\n\n\nTo contact us: \nHardman & Co\n11/12 Tokenhouse Yard \nLondon\nEC2R 7AS\n\n\nContacts:\nDr Martin Hall\[email protected] \nDr Dorothea Hill\[email protected]\nDr Gregoire Pave\[email protected]\nTelephone: +44 20 7929 3399\nFollow us on Twitter @HardmanandCo\n\n\n\n\nwww.hardmanandco.com \nAbout Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.\nHardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.\nOur research is provided for the use of the professional investment community, market counterparties and sophisticated and high net ...